- Home
- ARE vs ELAN Comparison
ARE vs ELAN Comparison
Compare ARE & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARE | ELAN |
|---|---|---|
| Founded | 1994 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.3B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARE | ELAN |
|---|---|---|
| Price | $59.69 | $24.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $58.33 | $24.44 |
| AVG Volume (30 Days) | 2.3M | ★ 4.7M |
| Earning Date | 01-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 8.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $3,058,395,000.00 | ★ $4,591,000,000.00 |
| Revenue This Year | N/A | $7.25 |
| Revenue Next Year | N/A | $5.69 |
| P/E Ratio | ★ N/A | $351.79 |
| Revenue Growth | N/A | ★ 3.08 |
| 52 Week Low | $44.10 | $8.02 |
| 52 Week High | $105.14 | $25.29 |
Technical Indicators
Market Signals| Indicator | ARE | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 75.04 | 62.66 |
| Support Level | $56.07 | $23.67 |
| Resistance Level | $58.22 | $25.29 |
| Average True Range (ATR) | 1.66 | 0.77 |
| MACD | 0.79 | 0.08 |
| Stochastic Oscillator | 99.86 | 77.03 |
Price Performance
Historical ComparisonAbout ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.